AU2006293814B2 - Method for obtaining human smooth muscular cells and uses thereof - Google Patents
Method for obtaining human smooth muscular cells and uses thereof Download PDFInfo
- Publication number
- AU2006293814B2 AU2006293814B2 AU2006293814A AU2006293814A AU2006293814B2 AU 2006293814 B2 AU2006293814 B2 AU 2006293814B2 AU 2006293814 A AU2006293814 A AU 2006293814A AU 2006293814 A AU2006293814 A AU 2006293814A AU 2006293814 B2 AU2006293814 B2 AU 2006293814B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- medium
- human
- culture
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 230000003387 muscular Effects 0.000 title claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 173
- 210000002363 skeletal muscle cell Anatomy 0.000 claims abstract description 69
- 238000001574 biopsy Methods 0.000 claims abstract description 20
- 102000006783 calponin Human genes 0.000 claims abstract description 17
- 108010086826 calponin Proteins 0.000 claims abstract description 17
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 73
- 239000002609 medium Substances 0.000 claims description 65
- 238000001964 muscle biopsy Methods 0.000 claims description 43
- 238000000338 in vitro Methods 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 21
- 230000004069 differentiation Effects 0.000 claims description 18
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 17
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102100036912 Desmin Human genes 0.000 claims description 15
- 108010044052 Desmin Proteins 0.000 claims description 15
- 210000005045 desmin Anatomy 0.000 claims description 15
- 108700038605 human Smooth muscle Proteins 0.000 claims description 14
- 102000043827 human Smooth muscle Human genes 0.000 claims description 14
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 13
- 101710099061 Myogenic factor 5 Proteins 0.000 claims description 13
- 102100032970 Myogenin Human genes 0.000 claims description 13
- 108010056785 Myogenin Proteins 0.000 claims description 13
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 210000000663 muscle cell Anatomy 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 229930182831 D-valine Natural products 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 108010081589 Becaplermin Proteins 0.000 claims description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 125000003580 L-valyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims description 2
- 108010052014 Liberase Proteins 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- -1 FGFb Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 108700012920 TNF Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 24
- 239000000203 mixture Substances 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 15
- 241000282412 Homo Species 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000028867 ischemia Diseases 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract description 3
- 230000000250 revascularization Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 26
- 210000002889 endothelial cell Anatomy 0.000 description 22
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 19
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 19
- 230000001173 tumoral effect Effects 0.000 description 12
- 102000004446 Serum Response Factor Human genes 0.000 description 11
- 108010042291 Serum Response Factor Proteins 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 210000005166 vasculature Anatomy 0.000 description 7
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000001114 myogenic effect Effects 0.000 description 4
- 210000003668 pericyte Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 238000011122 anti-angiogenic therapy Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 101100286588 Mus musculus Igfl gene Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 208000009443 Vascular Malformations Diseases 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000037998 chronic venous disease Diseases 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 241000501458 Cultus Species 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 description 1
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108090000333 Transgelin Proteins 0.000 description 1
- 102000003932 Transgelin Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 108010055756 hemalin Proteins 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700038606 rat Smooth muscle Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Excavating Of Shafts Or Tunnels (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0509557 | 2005-09-19 | ||
| FR0509557A FR2890977A1 (fr) | 2005-09-19 | 2005-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
| PCT/FR2006/002144 WO2007034069A1 (fr) | 2005-09-19 | 2006-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006293814A1 AU2006293814A1 (en) | 2007-03-29 |
| AU2006293814B2 true AU2006293814B2 (en) | 2011-09-29 |
Family
ID=36587333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006293814A Ceased AU2006293814B2 (en) | 2005-09-19 | 2006-09-19 | Method for obtaining human smooth muscular cells and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090269310A1 (enExample) |
| EP (1) | EP1934333B9 (enExample) |
| JP (1) | JP2009508511A (enExample) |
| CN (1) | CN101310013B (enExample) |
| AT (1) | ATE531791T1 (enExample) |
| AU (1) | AU2006293814B2 (enExample) |
| CA (1) | CA2622916A1 (enExample) |
| FR (1) | FR2890977A1 (enExample) |
| IL (1) | IL190289A0 (enExample) |
| WO (1) | WO2007034069A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2909559B1 (fr) * | 2006-12-06 | 2012-09-07 | Inst Vaisseaux Et Du Sang | Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation |
| KR101724639B1 (ko) * | 2008-11-04 | 2017-04-07 | 리젠메드 (케이만) 엘티디. | 세포-지지체 구조물 |
| HRP20230474T1 (hr) * | 2017-12-14 | 2023-07-21 | Innovacell Ag | Postupci za dobivanje stanica izvedenih iz mišića |
| CN112119155A (zh) * | 2018-05-08 | 2020-12-22 | 苏黎士大学 | 用于无异种产生hMPC群的方法 |
| EP4397752A3 (en) * | 2019-03-22 | 2024-10-02 | Innovacell GmbH | Methods for obtaining induced smooth muscle cells |
| CN120418415A (zh) * | 2022-12-28 | 2025-08-01 | 因特斯迪姆株式会社 | 细胞组合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2810045B1 (fr) * | 2000-06-07 | 2004-09-03 | Assist Publ Hopitaux De Paris | Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations |
| US20040247575A1 (en) * | 2003-06-03 | 2004-12-09 | Caplice Noel M. | Smooth muscle progenitor cells |
-
2005
- 2005-09-19 FR FR0509557A patent/FR2890977A1/fr not_active Withdrawn
-
2006
- 2006-09-19 EP EP06808166A patent/EP1934333B9/fr not_active Not-in-force
- 2006-09-19 CN CN2006800428874A patent/CN101310013B/zh not_active Expired - Fee Related
- 2006-09-19 US US12/067,218 patent/US20090269310A1/en not_active Abandoned
- 2006-09-19 JP JP2008531733A patent/JP2009508511A/ja active Pending
- 2006-09-19 AU AU2006293814A patent/AU2006293814B2/en not_active Ceased
- 2006-09-19 AT AT06808166T patent/ATE531791T1/de active
- 2006-09-19 WO PCT/FR2006/002144 patent/WO2007034069A1/fr not_active Ceased
- 2006-09-19 CA CA002622916A patent/CA2622916A1/fr not_active Abandoned
-
2008
- 2008-03-19 IL IL190289A patent/IL190289A0/en unknown
Non-Patent Citations (2)
| Title |
|---|
| Le Ricousse-Roussanne et al (2004) Cardiovascular Research. Vol. 62, pps 176-184 * |
| Simper etal (2002) Circulation, Vol, 106, pps 1199-1204 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2890977A1 (fr) | 2007-03-23 |
| CN101310013B (zh) | 2011-09-07 |
| US20090269310A1 (en) | 2009-10-29 |
| EP1934333A1 (fr) | 2008-06-25 |
| CA2622916A1 (fr) | 2007-03-29 |
| IL190289A0 (en) | 2011-08-01 |
| ATE531791T1 (de) | 2011-11-15 |
| CN101310013A (zh) | 2008-11-19 |
| EP1934333B1 (fr) | 2011-11-02 |
| JP2009508511A (ja) | 2009-03-05 |
| AU2006293814A1 (en) | 2007-03-29 |
| EP1934333B9 (fr) | 2012-05-02 |
| WO2007034069A1 (fr) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7582292B2 (en) | Adipose tissue derived stromal cells for the treatment of neurological disorders | |
| DE60132429T2 (de) | Pluripotente aus von fettgewebe stammenden stromazellen erzeugte stammzellen und deren verwendung | |
| Mimeault et al. | Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies | |
| Torrente et al. | Intraarterial injection of muscle-derived CD34+ Sca-1+ stem cells restores dystrophin in mdx mice | |
| Zhang et al. | SDF‐1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction | |
| US20050169896A1 (en) | Bone marrow transplantation for treatment of stroke | |
| CA2464088A1 (en) | Stem cells that transform to beating cardiomyocytes | |
| Watanabe et al. | A human neural stem cell line provides neuroprotection and improves neurological performance by early intervention of neuroinflammatory system | |
| AU2013211934B2 (en) | Methods and compositions for modulating angiogenesis and vasculogenesis | |
| Itescu et al. | Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function | |
| AU2006293814B2 (en) | Method for obtaining human smooth muscular cells and uses thereof | |
| WO2016161290A1 (en) | Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms | |
| KR102630220B1 (ko) | 유도만능줄기세포-유래 중간엽 줄기세포 전구세포로부터 유래된 엑소좀을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
| Itescu et al. | Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function | |
| CN110551688B (zh) | 一种诱导体细胞重编程为造血干/祖细胞且促进造血干/祖细胞体外扩增的组合物及其应用 | |
| JP2011015609A (ja) | 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法 | |
| Kim et al. | Intracellular transduction of TAT-Hsp27 fusion protein enhancing cell survival and regeneration capacity of cardiac stem cells in acute myocardial infarction | |
| JP2009508511A5 (enExample) | ||
| Le Ricousse-Roussanne et al. | Ex vivo generation of mature and functional human smooth muscle cells differentiated from skeletal myoblasts | |
| WO2001048150A1 (en) | Cells capable of differentiating into heart muscle cells | |
| WO2007047963A2 (en) | Use of bone-marrow derived stem cells to treat ischemia | |
| Zhao et al. | Cardiac commitment driven by MyoD expression in pericardial stem cells | |
| US20190382728A1 (en) | Menstrual Blood Derived Angiogenesis Stimulatory Cells | |
| WO2007084487A2 (en) | Pericytes for use as stem cells | |
| US20090304650A1 (en) | Repair of the Bone Marrow Vasculature |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |